Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

This study evaluates the safety and tolerability of combining venetoclax with Vyxeos (CPX-351) in pediatric and young adult patients with acute leukemia that has come back or not responded to treatment.

Trial Details

NCT ID
NCT03826992
Phase
PHASE1
Sponsor
Children's Hospital Medical Center, Cincinnati
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Vyxeos
  • Venetoclax
Locations (sample)
  • Cincinnati, Ohio, United States|39.12711,-84.51439

Key Eligibility Criteria

  • Ages 1 Year to 39 Years
  • Diagnosis of one of the following:
  • Acute myeloid leukemia (AML), any subtype except
  • Patients with acute promyelocytic leukemia (APML) are NOT eligible

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →